No Data
No Data
Subdued Growth No Barrier To Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) Price
Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) price-to-sales (or "P/S") ratio of 5.5x may not look like an appealing investment opportunity when you consider close to half the companies in the Phar
Kangmei Pharmaceutical Logs Profit in Q1
Kangmei Pharmaceutical (SHA:600518) returned to an attributable profit of 7.5 million yuan, or 0.001 yuan per share, in the first quarter, according to a Tuesday filing with the Shanghai Stock Exchang
ST Kangmei (600518.SH) announced first-quarter results, net profit of 7.4713 million yuan
ST Kangmei (600518.SH) released its report for the first quarter of 2024. The company achieved operating income of 1 during the reporting period...
The Strong Earnings Posted By Kangmei Pharmaceutical (SHSE:600518) Are A Good Indication Of The Strength Of The Business
Even though Kangmei Pharmaceutical Co., Ltd. (SHSE:600518 ) posted strong earnings, investors appeared to be underwhelmed. We have done some analysis and have found some comforting factors beneath th
Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) On An Uptrend: Could Fundamentals Be Driving The Stock?
Kangmei Pharmaceutical's (SHSE:600518) stock up by 6.1% over the past three months. Given that stock prices are usually aligned with a company's financial performance in the long-term, we decided to
Kangmei Pharmaceutical Returns to Profit in 2023; Shares Decline 4%
Kangmei Pharmaceutical (SHA:600518) returned to an attributable profit of 102.5 million yuan in 2023 from a loss of 2.69 billion yuan in 2022, according to a Monday filing with the Shanghai bourse. Ea
No Data